

Magmilor (nifuratel).

Contributors

Calmic Ltd.

Publication/Creation

[approximately 1968]

Persistent URL

<https://wellcomecollection.org/works/eukhmkab>

License and attribution



Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome
collection**

Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

MAGMILOR

(NIFURATEL)




For the treatment of vulvo-vaginitis and leucorrhoea due to infection by *Trichomonas vaginalis* and *Candida albicans*.

MAGMILOR

(NIFURATEL)

Magmilor is a nitrofuran derivative. The approved name is Nifuratel and has the chemical structure shown below:



(N-(5-nitro-2-furfurylidene)-3-amino-5-methylmercaptomethyl-2-oxazolidinone)

THE PROBLEM

In a study of 536 cases of vulvo-vaginitis, (all between the ages of 15–45 years) the laboratory investigations revealed the causative organisms to be as follows:

Trichomonas vaginalis	76.3%
Candida albicans	8.2%
Both Organisms Together	2.8%

(Gioccoli et al)

However, even where laboratory facilities are available to the general practitioner, specific treatment after laboratory confirmation of diagnosis must involve delay in starting treatment.

A systemic treatment for trichomoniasis is essential for the control of infection in the Bartholin's glands and Skene's tubules, whereas a topical treatment may be more effective against organisms in the vagina. Reports indicate, moreover, that treatment with a specific trichomonacide can exacerbate latent candidal infections (Beveridge). Co-prescribing a specific topical fungicide with the systemic trichomonacide may be successful, but such treatment can engender the hazards of incompatibility and insufficient dosage of either drug.

THE SOLUTION

Magmilor offers a solution which overcomes all these problems. It is the first drug available having both topical activity against *Candida albicans* as well as systemic and topical activity against *Trichomonas vaginalis*. Magmilor Pessaries and Oral Tablets used together, provide the topical and systemic concentration required to eliminate all sensitive organisms. Magmilor treatment avoids delays incurred while seeking laboratory confirmation of diagnosis since it makes such confirmations superfluous in most cases. Incompatibility of drugs or exacerbation of sub-clinical candidal infections are likewise obviated.

The use of Magmilor Vaginal Pessaries and Oral Tablets together ensures rapid symptomatic relief followed by the elimination of *Trichomonas* and *Candida* from all affected parts – Bartholin's glands, Skene's tubules and from the vagina.

The clinical trials show that Magmilor attained 88.2% of successful results in trichomoniasis and 70% in mycosis.*

*Prof. G. Chappaz – Universitaire de Reims, France

There was a rapid improvement in the clinical symptoms and disappearance of the leucorrhoea.*

*R. Leoni – University of Florence, Italy

Magmilor is the only drug to date available with such a wide range of activity. Its use is recommended especially in colpitis due to non-specific infections and *Trichomonas vaginalis*.*

*Prof. M. Magara – Nippon Medical School

TERATOGENICITY

As with all new drugs Magmilor has been thoroughly investigated for the hazard of teratogenicity. Animal studies in Italy, France and England on mice, rats and rabbits failed to show any malformations which could be attributed to Magmilor. In addition to the animal studies, clinical trials in Italy, France, Switzerland and Spain where this drug has been available since 1965 amount to 3,000 cases of vaginitis including 53 pregnant women.

As a routine precaution during the first 12 weeks of pregnancy it is recommended that treatment with Magmilor should be limited to the use of the pessaries.

DOSAGE

This has been investigated by many experimenters and the results have shown that optimum cures can be obtained by the following treatment course.

Oral Tablets: One tablet three times a day after meals for seven days both for the woman and her partner.

Pessaries. One pessary to be inserted, on retiring at night, high into the vagina preferably into the posterior fornix, for ten consecutive nights.

The course of treatment may be repeated if necessary. If pessaries only are prescribed then treatment should be extended for twenty nights.

SIDE EFFECTS

Published clinical reports are now available describing treatment of over 3,000 patients and male partners. From these cases there were a few reports of minor abdominal discomfort, but on no occasion was it found necessary to discontinue treatment because of the severity of side-effects. Slight interaction with alcohol makes it inadvisable to take excessive quantities whilst undergoing treatment. There is no evidence, however, of severe intolerance in patients drinking normal quantities of alcohol.

PACKS

Magmilor is available as a treatment pack comprising 21 oral tablets and 10 pessaries.

The tablets and pessaries are also available in individual packs.

BASIC N.H.S. Price:

Treatment Pack	29/-
21 Oral Tablets	16/10
10 Vaginal Tablets	12/6
Plus P.T.	

REFERENCES

- M. Arnold: *Therapeutische Umschau* – 23, 9, 1966
- M. Arnold and J. Delnon: *Therapeutische Umschau* – 22, 10, 490, 1965
- M. M. Beveridge: *Brit. J. Ven. Dis.* – 38, 220, 1962
- J. M. Carrera and S. Dexeus: *Rev. Esp. de Obst. y Ginec.* – XXV, 308, 1966
- G. Chappaz and P. Bertrand: *Gynaekologia* – 160, 17, 1965 – 161, 36, 1966
- F. Coppi and V. Bertagnolli: *Urologia* – XXXII, VI, 1965
- S. Cosciani-Cunico: *Rass. di Urologia e Nefrologia* – III, 4, 1965
- A. Giocoli, A. Digesu and C. Cascella – *Edizioni Minerva Med* – 1967
- S. Imperato: *L'Igiene Moderna* – 56, 9–10, 1963
- R. Leoni: *Riv. di Ost. e Ginec.* – 19, 1964
- M. Magara: Communication made at the Congress of East Japan
Chemotherapeutic Association – Tokyo, 5th November, 1966
- I. Sagone: *Minerva Ginecologica* – 17, 13, 1965
- A. Sarnella: *Riv. di Ost. e Ginec. Pratica* – XLVIII, 7, 1966
- R. Scuri: *Chimie Therapeutique* – 2, 181, 1964
- R. Scuri and L. Failla: *Il Farmaco* – Ed. Sc. 19, 301, 1964
- E. Vartiainen and O. Widholm: *Duodecim* – 82, 755, 1966
- A. Weidenbach and L. Frölich – *J. Soc & Gyn.*, III, 1, 15, 1968



U.K. PATENT No. 969,126
Original Synthesis by Polichimica s.a.p.

CALMIC LIMITED CREWE

MAGMILOR

MAGMILOR COMBINED SYSTEMIC AND TOPICAL TREATMENT

* Complete treatment for vulvo-vaginitis and leucorrhoea.



* Inhibits sensitive organisms in all affected parts – Bartholin's glands, Skene's tubules and vagina.

* Provides immediate broad-spectrum treatment.

* Does not encourage Candidal overgrowth.


* Avoids the hazards of incompatibility when co-prescribing.

* Oral Tablets also provide treatment for male partner.



trichomonas v.

mycetes



extra-vaginal sources of infection



trichomoniasis in the partner